FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 1 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		5,498,410		Gleich	03-12-1996
		5,679,647		Carson et al.	10-21-1997
		5,681,555		Gleich	10-28-1997
		5,726,160		McMichael	03-10-1998
		5,908,620		Tu et al.	06-01-1999
		5,932,556		Tam	08-03-1999
		5,955,059		Gilchrest et al.	09-21-1999
		5,955,442		McMichael	09-21-1999
		5,994,315		Nyce et al.	11-30-1999
		6,025,339		Nyce et al.	02-15-2000
		6,040,296		Nyce et al.	04-24-2000
		6,090,791		Sato et al.	07-18-2000
		6,096,721		McMichael	08-01-2000
		6,100,244		McMichael	07-18-2000
		6,221,882		Macfarlane	04-24-2001
		6,339,630		Macfarlane	06-04-2002
		6,426,336	B1	Carson et al.	07-30-2002
		6,479,504		Macfarlane et al.	11-12-2002
		6,498,148	B1	Raz	12-24-2002
		6,514,948	B1	Raz et al.	02-04-2003
		6,521,637		Macfarlane	02-18-2003
		6,552,006	B2	Raz et al.	04-22-2003
		6,558,670	B1	Friede et al.	05-06-2003
		6,562,798	B1	Schwartz	05-13-2003
		6,589,940	B1	Raz et al.	07-08-2003
		6,610,661	B1	Carson et al.	08-26-2003
		6,635,624		Davis et al.	09-02-1998
		6,787,524	B2	Chang et al.	09-07-2004
		6,943,240		Bauer et al.	09-13-2005
		6,951,845	B2	Carson et al.	10-04-2005
		6,977,245	B2	Klinman et al.	12-20-2005
		7,001,890		Wagner et al.	02-26-2006
		7,223,741	B2	Krieg	05-29-2007
		2002-0086295	A1	Raz et al.	07-04-2002
		2002-0102255	A1	Chang	08-01-2002
		2003-0027782	A1	Carson et al.	02-06-2003
		2003-0049266	A1	Fearon et al.	03-13-2003

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 2 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		2003-0064064	A1	Dina et al.	04-03-2003
		2003-0078223	A1	Raz et al.	04-24-2003
		2003-0092663	A1	Raz et al.	05-15-2003
		2003-0119773	A1	Raz et al.	06-26-2003
		2003-0224010	A1	Davis et al.	12-04-2003
		2003-0232856	A1	Macfarlane	12-18-2003
		2004-0006034	A1	Raz et al.	01-08-2004
		2004-0009949	A1	Krieg	01-15-2004
		2004-0038922	A1	Haensler et al.	02-26-2004
		2004-0053880	A1	Krieg	03-18-2004
		2004-0064064	A1	Zhou et al.	04-01-2004
		2004-0067902	A9	Bratzler et al.	04-08-2004
		2004-0067905	A1	Krieg	04-08-2004
		2004-0087534	A1	Krieg et al.	05-06-2004
		2004-0087538	A1	Krieg et al.	05-06-2004
		2004-0092472	A1	Krieg	05-13-2004
		2004-0106568	A1	Krieg et al.	06-03-2004
		2004-0131628	A1	Bratzler et al.	07-08-2004
		2004-0132685	A1	Krieg et al.	07-08-2004
		2004-0142469	A1	Krieg et al.	07-22-2004
		2004-0143112	A1	Krieg et al.	07-22-2004
		2004-0147468	A1	Krieg et al.	07-29-2004
		2004-0152649	A1	Krieg	08-05-2004
		2004-0152656	A1	Krieg et al.	08-05-2004
		2004-0152657	A1	Krieg et al.	08-05-2004
		2004-0162258	A1	Krieg et al.	08-19-2004
		2004-0162262	A1	Krieg et al.	08-19-2004
		2004-0167089	A1	Krieg et al.	08-26-2004
		2004-0171150	A1	Krieg et al.	09-02-2004
		2004-0171571	A1	Krieg et al.	09-02-2004
		2004-0181045	A1	Krieg et al.	09-16-2004
		2004-0198680	A1	Krieg	10-07-2004
		2004-0198688	A1	Krieg et al.	10-07-2004
		2004-0229835	A1	Krieg et al.	11-18-2004
		2004-0234512	A1	Wagner et al.	11-25-2004
		2004-0235770	A1	Davis et al.	11-25-2004
		2004-0235774	A1	Bratzler et al.	11-25-2004
		2004-0235777	A1	Wagner et al.	11-25-2004
		2004-0235778	A1	Wagner et al.	11-25-2004

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 3 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		2004-0247662	A1	Dow et al.	12-09-2004
		2004-0248837	A1	Raz et al.	12-09-2004
		2004-0266719	A1	McCluskie et al.	12-30-2004
		2005-0004061	A1	Krieg et al.	01-06-2005
		2005-0004062	A1	Krieg et al.	01-06-2005
		2005-0009774	A1	Krieg et al.	01-13-2005
		2005-0013812	A1	Dow et al.	01-20-2005
		2005-0032734	A1	Davis et al.	02-10-2005
		2005-0032736	A1	Krieg et al.	02-10-2005
		2005-0037403	A1	Krieg et al.	02-17-2005
		2005-0037985	A1	Krieg et al.	02-17-2005
		2005-0042203	A1	Davis et al.	02-24-2005
		2005-0043529	A1	Davis et al.	02-24-2005
		2005-0049215	A1	Krieg et al.	03-03-2005
		2005-0049216	A1	Krieg et al.	03-03-2005
		2005-0054601	A1	Wagner et al.	03-10-2005
		2005-0054602	A1	Krieg et al.	03-10-2005
		2005-0059619	A1	Krieg et al.	03-17-2005
		2005-0059625	A1	Krieg et al.	03-17-2005
		2005-0064401	A1	Olek et al.	03-24-2005
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0075302	A1	Hutcherson et al.	04-07-2005
		2005-0100983	A1	Bauer et al.	05-12-2005
		2005-0101554	A1	Krieg et al.	05-12-2005
		2005-0101557	A1	Krieg et al.	05-12-2005
		2005-0119273	A1	Lipford et al.	06-02-2005
		2005-0123523	A1	Krieg et al.	06-09-2005
		2005-0130911	A1	Uhlmann et al.	06-16-2005
		2005-0148537	A1	Krieg et al.	07-07-2005
		2005-0169888	A1	Hartman et al.	08-04-2005
		2005-0171047	A1	Krieg et al.	08-04-2005
		2005-0181422	A1	Bauer et al.	08-18-2005
		2005-0182017	A1	Krieg	08-18-2005
		2005-0197314	A1	Krieg et al.	09-08-2005
		2005-0209183	A1	Kippenberger et al.	09-22-2005
		2005-0209184	A1	Klinman et al.	09-22-2005
		2005-0215500	A1	Krieg et al.	09-29-2005
		2005-0215501	A1	Lipford et al.	09-29-2005
		2005-0233995		Krieg et al	04-23-2004

/NMM/ 08/14/2008 (08/14/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 4 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		2005-0233999	A1	Krieg et al.	10-27-2005
		2005-0239732	A1	Krieg et al.	10-27-2005
		2005-0239734	A1	Jurk et al.	10-27-2005
		2005-0239734	A1	Uhlmann et al.	10-27-2005
		2005-0239736	A1	Krieg et al.	10-27-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2005-0244379	A1	Krieg et al.	11-03-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0250726	A1	Krieg et al.	11-10-2005
		2005-0256073	A1	Lipford et al.	11-17-2005
		2005-0267057		Krieg	07-14-2003
		2005-0267064	A1	Krieg et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2006-0003955		Krieg et al.	02-25-2005
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006
		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875	A1	Krieg et al.	06-29-2006
		2006-0154890	A1	Bratzler et al.	07-13-2006
		2006-0171968	A1	Brimnes et al.	08-03-2006
		2006-0172966	A1	Lipford et al.	08-03-2006
		2006-0188913	A1	Krieg et al.	08-24-2006
		2006-0211639	A1	Bratzler et al.	09-21-2006
		2006-0211644	A1	Krieg et al.	09-21-2006
		2006-0229271	A1	Krieg et al.	10-12-2006
		2006-0241076	A1	Uhlmann et al.	10-26-2006
		2006-0246035		Ahluwalia et al.	04-26-2005
		2006-0065467	A1	Krieg et al.	03-22-2007
		2006-0286070	A1	Hartmann et al.	12-21-2006
		2006-0287263	A1	Davis et al.	12-21-2006
		2007-0009482	A1	Krieg et al.	01-11-2007
		2007-0010470	A1	Krieg et al.	01-11-2007
		2007-0037767	A1	Bratzler et al.	02-15-2007
		2007-0066553	A1	Krieg et al.	03-22-2007
		2007-0066554	A1	Krieg et al.	03-22-2007
		2007-0078104	A1	Krieg et al.	04-05-2007

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 5 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No.	U.S. Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		2007-0129320	A9	Davis et al.	06-07-2007
		2007-0142315	A1	Forsbach et al.	06-21-2007
		2007-0184465	A1	Wagner et al.	08-09-2007
		2007-0202128	A1	Krieg et al.	08-30-2007
		2007-0224210	A1	Krieg et al.	09-27-2007
		2007-0232622	A1	Lipford et al.	10-04-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		WO	96/32138	A1	Milkhaus Laboratory	10-17-1996	
		WO	99/52549	A1	SmithKline Beecham Biologicals S.A.	10-29-1999	
		WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract
		WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
		WO	00/61151	A2	The Government of the United States of America	10-19-2000	
		WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y-Abstract
		WO	04/007743	A2	Coley Pharmaceutical GmbH	01-22-2004	
		WO	04/026888	A2	Coley Pharmaceutical GmbH	04-01-2004	
		WO	04/094671	A2	Coley Pharmaceutical GmbH	11-04-2004	
		WO	06/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
		WO	07/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
		WO	07/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] National Institute of Health, Publication Number 97-4051, July 1997.	
		[No Author Listed] CpG oligonucleotide adjuvants modulate allergic response in mouse model. Allergy Medicine, NewsRx.com. January 16, 2000. (Jahnschmid)	
		[No Author Listed] Compound decreases need for steroids and reduces asthma symptoms. Allergy Medicine, NewsRx.com. January 16, 2000. (Milgrom)	
		ADEREM et al., How do you see CG? Cell. 2000 Dec 22;103(7):993-6.	
		AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43.	
		AGRAWAL et al., Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today. 2000 Feb;6(2):72-81.	
		AGRAWAL et al., Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol. 2004 Jan;4(1):127-38.	

/NMM/ 08/14/2008 (08/14/2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
				APPLICANT: Bratzler et al.	
Sheet	6	of	13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
		ASKENASE et al., Gee whiz: CpG DNA allergy therapy! J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):37-40.	
		BARNES et al., New treatments for asthma. European J Internal Medicine. 2000;11:9-20. Abstract Only.	
		BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 1999 Aug;97(4):699-705.	
		BOHLE et al., Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 1999 Jul;29(7):2344-53.	
		BRAZOLOT et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.	
		BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 1998 Dec 15;161(12):7054-62.	
		BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. Springer Semin Immunopathol. 2000;22(1-2):117-24.	
		BRUNNER et al., Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 1;165(11):6278-86.	
		CAMPBELL et al., Allergen immunotherapy: novel approaches in the management of allergic diseases and asthma. Clin Immunol. 2000 Dec;97(3):193-202.	
		CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
		CELLA et al., Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol. 2000 Oct;1(4):305-10.	
		CELLA et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999 Aug;5(8):919-23.	
		CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
		COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov;24(6):693-701.	
		COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004 Aug 13;22(23-24):3136-43.	
		CRETICOS et al., Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J Allergy Clin Immunol. 2002:109(4):741-3.	
		DAVIS, Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol. 2000;247:171-83.	
		DAVIS et al., CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909. Third Annual Conference on Vaccine Res. 2000. Abstract s25, number 47.	
		DURHAM et al., Immunotherapy and allergic inflammation. Clin Exp Allergy. 1991 Jan;21 Suppl 1:206-10.	
		DZIADZIO et al., Handbook of Experimental Pharmacology, Pharmacology and Therapeutics of	

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 7 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Asthma and COPD. 2004;161:273-85.	
		FORNADLEY et al., Allergy immunotherapy. Otolaryngol Clin North Am. 1998 Feb;31(1):111-27. Abstract Only.	
		GALLICHAN et al., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001 Mar 1;166(5):3451-7.	
		GAO et al., Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol. 2001 Jun 1;166(11):6855-60.	
		GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. Nat Biotechnol. 2000 May;18(5):491-2.	
		GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001 May-Jun;24(3):237-41.	
		HAFNER et al., Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 2001 Jul 15;61(14):5523-8.	
		HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 2003 Jun 2;21(19-20):2461-7.	
		HANCOCK et al., CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine. 2001 Sep 14;19(32):4874-82.	
		HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.	
		HARTMANN et al., Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000 Jan 15;164(2):944-53.	
		HEEG et al., CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000 Feb;121(2):87-97.	
		HOGG et al., The pathology of asthma. APMIS. 1997 Oct;105(10):735-45.	
		HOPKIN et al., Curbing the CpGs of Bacterial and Viral DNA. BioMedNet. 1999 Jun25; Issue 57.	
		HORNER et al., Microbial DNA and Host Immunity. Chapter 22:DNA-based immunotherapeutics for allergic disease. p279-87.	
		HORNER et al., Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol. 2002 Sep;110(3):413-20.	
		HORNER et al., Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol. 2002 Nov;110(5):706-12.	
		HUSSAIN et al., CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. Curr Drug Targets Inflamm Allergy. 2003 Sep;2(3):199-205.	
		HUSSAIN et al., DNA, the immune system, and atopic disease. J Investig Dermatol Symp Proc. 2004 Jan;9(1):23-8.	
		IKEDA et al., Microbial DNA and Host Immunity. Chapter 23: Immunostimulatory DNA for allergic asthma. p289.	
		INFANTE-DUARTE et al., Th1/Th2 balance in infection. Springer Semin Immunopathol. 1999;21(3):317-38.	
		IRWIN et al., Asthma may be reduced by vaccine from soil. The Daily Telegraph. 1999 Sep 5;6.	
		JAIN et al., Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model	

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
				APPLICANT: Bratzler et al.	
Sheet	8	of	13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1137-46.	
		JAIN et al., CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy. 2003 Oct;33(10):1330-5.	
		JAIN et al., CpG DNA: immunomodulation and remodelling of the asthmatic airway. Expert Opin Biol Ther. 2004 Sep;4(9):1533-40.	
		JAIN et al., CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol. 2002 Dec;110(6):867-72.	
		JAIN et al., The promise of CpG DNA in the treatment of asthma. Recent Res Develop Resp Crit Care Med. 2002;2:7-18.	
		JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15;161(6):3042-9.	
		JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):457-61.	
		JILEK et al., Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol. 2001 Mar 1;166(5):3612-21.	
		KANDIMALLA et al., Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther. 2002 Apr;4(2):122-9.	
		KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
		KITAGAKI et al., Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses. Clin Diagn Lab Immunol. 2002 Nov;9(6):1260-9.	
		KITAGAKI et al., Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. Clin Exp Immunol. 2006 Feb;143(2):249-59.	
		KITAGAKI et al., CpG oligonucleotides in asthma Microbial DNA and Host Immunity. Chapter 24. page 301.	
		KLINE et al., Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998 Mar 15;160(6):2555-9.	
		KLINE et al., Induction of oral tolerance by CpG-ODNs in a murine model of asthma. J Allergy Clin Immunol. 2004 Feb;113(2):S254. Abstract 915.	
		KLINE et al., DNA therapy for asthma. Curr Opin Allergy Clin Immunol. 2002 Feb;2(1):69-73.	
		KLINE et al., T-lymphocyte dysregulation in asthma. Proc Soc Exp Biol Med. 1994 Dec;207(3):243-53.	
		KLINE et al., Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol. 2000;247:211-25.	
		KLINE et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L170-9.	
		KLINMAN et al., CpG motifs as immune adjuvants. Vaccine. 1999 Jan;17(1):19-25.	
		KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
		KOHAMA et al., Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J Allergy Clin Immunol. 1999 Dec;104(6):1231-8.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 9 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7.	
		KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
		KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
		KRIEG et al., 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: 116.	
		KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	
		KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
		KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
		KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
		KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
		KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
		KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
		KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
		KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
		KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
		KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
		KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
		KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.	
		KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb;3(1):15-24.	
		KRIEG et al., Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30:105-18.	
		KRIEG et al., Chapter 17:Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
		KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
		KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	
		KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal	

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
				APPLICANT: Bratzler et al.	
Sheet	10	of	13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
		KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
		KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
		LeCLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997 Aug 1;179(2):97-106.	
		LEE et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. Immunology. 1998 Jul;94(3):285-9.	
		LEONARD et al., Interleukin-12: potential role in asthma therapy. BioDrugs. 2003;17(1):1-7.	
		LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept7;45(7):333A.	
		LUKACS et al., Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol. 1994 May;10(5):526-32.	
		LUKACS et al., C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation. J Leukoc Biol. 1996 Nov;60(5):573-8.	
		MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001 Aug;108(2):191-7.	
		MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.	
		McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1;161(9):4463-6.	
		McCLUSKIE et al., Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med. 1999 May;5(5):287-300.	
		McCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine, 18: 231-237, 2000.	
		McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22;19(7-8):950-7.	
		McCLUSKIE et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000;22(1-2):125-32.	
		McCLUSKIE et al., The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Investig Drugs. 2001 Jan;2(1):35-9.	
		METZGER et al., Oligonucleotide therapy of allergic asthma. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):260-6.	
		MOSMANN et al., The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996 Mar;17(3):138-46.	
		NORMAN et al., Immunotherapy: 1999-2004. J Allergy Clin Immunol. 2004 Jun;113(6):1013-23	
		PADRID et al., CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma. Am J Respir Cell Mol Biol. 1998 Apr;18(4):453-62.	
		PARK et al., The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J Allergy Clin Immunol. 2001	

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 11 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Oct;108(4):570-6.	
		PAYETTE et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.	
		PENG et al., CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int Immunol. 2001 Jan;13(1):3-11.	
		PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208.	
		PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	
		POLANCZYK et al., Immunostimulatory effects of DNA and CpG motifs. Cent Eur J of Immunol. 2000;25(3):160-6.	
		RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
		RAY et al., Oral pretreatment of mice with immunostimulatory CpG DNA induces reduced susceptibility to *Listeria monocytogenes*. Experimental Biology 2001. Orlando, Florida, USA. March 31-April 4, 2001. Abstracts, part II. FASEB J. 2001 Mar 8;15(5):A1007.	
		RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
		ROBINSON et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992 Jan 30;326(5):298-304.	
		ROMAN et al., Gene immunization for allergic disorders. Springer Semin Immunopathol. 1997;19(2):223-32.	
		SAITO et al., Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology. 2001 Oct;104(2):226-34.	
		SATOH et al., Morphological and immunohistochemical characteristics of the heterogeneous prostate-like glands (paraurethral gland) seen in female Brown-Norway rats. Toxicol Pathol. 2001 Mar-Apr;29(2):237-41.	
		SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31.	
		SEREBRISKY et al., CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol. 2000 Nov 15;165(10):5906-12.	
		SESTER et al., Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol. 2000 Oct 15;165(8):4165-73.	
		SIEGRIST et al., Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine. 2004 Dec 16;23(5):615-22.	
		SIMONS et al., Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004 Jun;113(6):1144-51.	
		SIOLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997 Apr 10;177(1):69-76.	
		SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
		SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
	APPLICANT: Bratzler et al.	
Sheet 12 of 13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		SPARWASSER et al., Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol. 1999 Feb 15;162(4):2368-74.	
		SPEISER et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46.	
		SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther. 2002 Feb;4(1):64-71.	
		STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
		STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997, ch11: 241-64.	
		SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998 Dec 21;188(12):2335-42.	
		SUR et al., Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 1999 May 15;162(10):6284-93.	
		TIGHE et al., Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):124-34.	
		TIGHE et al., Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol. 2000 Jul;30(7):1939-47.	
		TOKUNAGA, Response of the organism to DNA – With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese.	Yes
		TORTORA et al., Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res. 2000 Jun;6(6):2506-12.	
		TOURNOY et al., Is Th1 the solution for Th2 in asthma? Clin Exp Allergy. 2002 Jan;32(1):17-29.	
		UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17.	
		VAN OJIK et al., Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. Ann Oncol. 2003;13:157. Abstract 579O.	
		VERTHELYI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.	
		WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Aug;8(4):351-6.	
		WEERATNA et al., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol. 2001 Dec;32(1):65-71.	
		WEERATNA et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000 Mar 6;18(17):1755-62.	
		WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.	
		WEINER et al., The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol. 2000 Oct;68(4):455-63.	
		WOHLLEBEN et al., Atopic disorders: a vaccine around the corner? Trends Immunol. 2001 Nov;22(11):618-26.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997	

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/776,479	ATTY. DOCKET NO.: C1037.70013US00
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: 02/02/01	CONFIRMATION NO.: 7139
				APPLICANT: Bratzler et al.	
Sheet	13	of	13	GROUP ART UNIT: 1645	EXAMINER: N. M. Minnifield

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Oct;7(5):495-502.	
		ZIMMERMANN et al., CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998 Apr 15;160(8):3627-30.	

EXAMINER: /N. M. Minnifield/ (08/14/2008)	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/